Drugs Xagena
The Food and Drug Administration ( FDA ) warned the public that Azithromycin ( Zithromax or Zmax ) can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm. Patients at particular risk for developing this condition include those with known risk factors such as existing QT interval prolongation, low blood levels of potassium or magnesium, a slower than normal heart rate, or use of certain drugs used to treat abnormal heart rhythms, or arrhythmias.
FDA has issued a Drug Safety Communication as a result of a review of a study by medical researchers as well as another study by a manufacturer of the drug that assessed the potential for Azithromycin to cause abnormal changes in the electrical activity of the heart.
FDA previously released a Statement on May 17, 2012, about a study that compared the risks of cardiovascular death in patients treated with the antibacterial drugs Azithromycin, Amoxicillin, Ciprofloxacin ( Cipro ), and Levofloxacin ( Levaquin ), or no antibacterial drug.
The study reported an increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of Azithromycin ( Zithromax ) compared to persons treated with Amoxicillin, Ciprofloxacin, or no drug. The risks of cardiovascular death associated with Levofloxacin treatment were similar to those associated with Azithromycin treatment.
FDA-approved indications for Azithromycin include: acute bacterial exacerbations of chronic obstructive pulmonary disease, acute bacterial sinusitis, community-acquired pneumonia, pharyngitis / tonsillitis, uncomplicated skin and skin structure infections, urethritis and cervicitis, genital ulcer disease.
Recommendation
Health care professionals should consider the risk of torsades de pointes and fatal heart rhythms with Azithromycin when considering treatment options for patients who are already at risk for cardiovascular events. FDA notes that the potential risk of QT prolongation with Azithromycin should be placed in appropriate context when choosing an antibacterial drug. Alternative drugs in the macrolide class, or non-macrolides such as the fluoroquinolones, also have the potential for QT prolongation or other significant side effects that should be considered when choosing an antibacterial drug. ( Xagena )
Source: FDA, 2013
XagenaMedicine_2013
